News & Publications

The NLJ notes Mick Bain’s extensive work as a business advisor to a myriad of tech companies at all stages.

The 2019 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.

The 2019 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.

The 2019 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest.

WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

New York–based startup Kindur has launched its innovative online wealth management platform with a mission: to help retirees use their savings wisely and efficiently.

On May 8, 2019, Altiostar, the pioneer in open virtualized RAN (open vRAN) technology, announced that it closed a Series C round of financing with Rakuten coming on board as an investor.

Biotechnology company Inozyme Pharma, Inc. announced that it raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments.

WilmerHale represented Stash, the financial platform revolutionizing how millions of Americans invest and save, in its $65 million Series E funding.  

This article discusses key areas that startups need to focus on as they mature in order to sidestep “business-busting” distractions and lay the groundwork for healthy company culture. 

In 2018, we served as counsel in more than 200 venture financings raising close to $4.5 billion, including some of the largest and most prominent deals of the year.

Palo Alto-based Ashwin Gokhale’s path to partnership is profiled in the Law.com series “How I Made Partner.”

Affirmed currently has more than 100 customers around the world, including many Tier 1 and Tier 2 mobile service providers.

The article provides a recap of the 2018 market for early-stage public biotech companies, a peek into 2019 conditions, and goes on to outline how early-stage public companies can position themselves to maximize and maintain investor engagement and to execute financings from a position of strength.

The practice group is said to demonstrate a deep understanding of the business and regulatory issues driving the industry, with specialty areas including intellectual property litigation, securities, licensing, corporate law and taxation providing the most benefit to clients.